Impact of Thrombotic Events in PV | MPN Quality Initiatives

IMPACT ON

PATIENTS

HIGHER RISK OF TEs IN PV1

In a population-based
study* of 9429 patients
with MPNs,
including
3001 with PV

In a population-based study* of 9429 patients
with MPNs,
including 3001 with PV

4.2x
risk of thrombosis

in patients with PV
vs matched controls

HR, 4.2; CI, 3.5–5.0
4.2x
risk of thrombosis

in patients with PV vs matched controls HR, 4.2; CI, 3.5–5.0

*Population-based study based on Swedish Cancer Registry data for 1987-2009 in 9429 patients with MPNs. 9429 MPN patients (PV=3001, ET=3462, PMF=1488, and MPN-U=1478) and 35,820 matched controls were identified and included in the study. Hazard ratio for thrombosis at 3 months post-diagnosis was 4.2 for PV (95% CI, 3.5–5.0) vs
4.0 for all MPNs (95% CI, 3.6–4.4).1

CI=confidence interval; ET=essential
thrombocythemia; HR=hazard ratio;
MPN=myeloproliferative neoplasm;
MPN-U=myeloproliferative neoplasm unclassifiable;
PMF=primary myelofibrosis; PV=polycythemia vera;
TEs=thrombotic events.
Consider

Quality

Initiatives

for patients with advanced PV who are at risk of a thrombotic event8,9

  • Manage appropriate blood counts
  • Monitor disease-related symptoms
  • Optimize dosing
Implement a Quality Initiative Today

IMPACT ON THE

HEALTHCARE SYSTEM

A retrospective
cross-sectional analysis*
of US healthcare resource
utilization and costs
for adult patients with
PV and TEs demonstrated

A retrospective cross-sectional analysis*
of US healthcare resource utilization and costs
for adult patients with PV and TEs demonstrated

Patients with TEs
demand greater
healthcare
resources vs those
without TEs7

3x the cost of healthcare7
3x the cost of healthcare7

$45,040 mean total
annual costs for patients
with PV and TEs
vs
$16,438 for those
without TEs (P < 0.001)

$45,040 mean total annual costs for patients with PV and TEs vs $16,438 for those without TEs (P < 0.001)

*Retrospective cross-sectional database analysis including 1322 adult patients with a PV diagnosis who were newly treated with hydroxyurea and continuously enrolled in medical and pharmacy benefit plans for
≥12 months pre- and post-index. Healthcare resource utilization and costs were analyzed in a subgroup analysis comparing patients who had TEs in the 12-month follow-up period with those who did not.7

Consider

Quality

Initiatives

for patients with advanced PV who are at risk of a thrombotic event

  • Manage appropriate blood counts
  • Monitor disease-related symptoms
  • Optimize dosing
Implement a Quality Initiative Today